Beeline Medicines

Precision immunology spinout of 5 assets from Bristol-Myers Squibb (July 2025), backed by $300M from Bain Capital; not independently publicly traded

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
TLR7/8Small molecule
Systemic Lupus Erythematosus
Phase 2
TYK2Small molecule
Psoriasis
Phase 1
IL-2 receptor alpha (IL2RA)Biologic (subtype unspecified)
Atopic Dermatitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
April 2030 (1)
AfimetoranPhase 2/3Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Est. primary completion 2030-04 · NCT07881120 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 September 2026Topline resultAfimetoranGlobal Phase 2 of afimetoran in systemic lupus erythematosus met its primary endpoint
Beeline Medicines · Source ↗

Financial reports

No financial reports recorded.